Vimentin drives EMT and metastasis in several solid cancers; upregulation of Vimentin is associated with poor clinical outcome in several cancers as acute myeloid leukemia [52], breast cancers [53] and oral squamous cell carcinomas [54]. This evidence concerns the gene VIM and breast carcinoma.